Profusa Regains Nasdaq Compliance, Removes Delisting Threat
PFSA is trading near its 52-week low of $2.35 (2.1% below the low) on light trading volume (0.1× avg).
Summary
Nasdaq confirmed Profusa meets the bid-price and equity listing rules, removing the immediate delisting risk that has hung over the stock since the July reverse split. The company remains under a one-year Mandatory Panel Monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(B), so any equity shortfall would trigger a swift delist determination. During the monitor, if Nasdaq finds the company out of compliance with the Equity Rule, no compliance plan or additional time will be granted, nor a cure or compliance period under Rule 5810(c)(3). The company may appeal a Staff Delisting Determination pursuant to Nasdaq Listing Rule 5815, and requesting a hearing would stay any further action by Nasdaq at least until the hearing is held and any extension granted by the Panel expires. This follows a series of compliance struggles, including a 1-for-25 reverse split in July and a discretionary reverse split authorization sought in August. The confirmation stabilizes the listing but does not address the underlying financial weakness: Q2 loss widened to $8.8M and cash fell to $0.7M. Traders should note the stock trades near its 52-week low at $2.30, and the monitor period keeps delisting risk alive.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — On September 9, 2026, Profusa received Nasdaq confirmation of compliance with the Bid Price Rule and Equity Rule, subject to a one-year Mandatory Panel Monitor under Rule 5815(d)(4)(B).
- Compliance Confirmation
- The one-year Mandatory Panel Monitor is pursuant to Nasdaq Listing Rule 5815(d)(4)(B).
- Monitor Conditions
- During the monitor, if Nasdaq finds the company out of compliance with the Equity Rule, no compliance plan or additional time will be granted, nor a cure or compliance period under Rule 5810(c)(3).
- Appeal Rights
- The company may appeal a Staff Delisting Determination pursuant to Nasdaq Listing Rule 5815.
- Requesting a hearing would stay any further action by Nasdaq at least until the hearing is held and any extension granted by the Panel expires.
All 4 details
- The one-year Mandatory Panel Monitor is pursuant to Nasdaq Listing Rule 5815(d)(4)(B).
- During the monitor, if Nasdaq finds the company out of compliance with the Equity Rule, no compliance plan or additional time will be granted, nor a cure or compliance period under Rule 5810(c)(3).
- The company may appeal a Staff Delisting Determination pursuant to Nasdaq Listing Rule 5815.
- Requesting a hearing would stay any further action by Nasdaq at least until the hearing is held and any extension granted by the Panel expires.
- Compliance Confirmation
At the time of this announcement, PFSA was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.35 to $3,417.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.